Roth Capital initiated coverage on The Beauty Health Company with a new price target
$SKIN
Medical/Dental Instruments
Health Care
Roth Capital initiated coverage of The Beauty Health Company with a rating of Buy and set a new price target of $3.50
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2025 | $3.50 | Buy | Roth Capital |
| 11/15/2023 | $11.00 → $1.50 | Buy → Hold | Jefferies |
| 11/14/2023 | $10.00 → $2.50 | Buy → Hold | Canaccord Genuity |
| 11/14/2023 | Neutral → Underweight | JP Morgan | |
| 11/14/2023 | $12.00 → $2.00 | Overweight → Underweight | Piper Sandler |
| 11/14/2023 | $9.00 → $2.50 | Outperform → Market Perform | TD Cowen |
| 11/14/2023 | Buy → Hold | The Benchmark Company | |
| 11/14/2023 | Mkt Perform → Underperform | Raymond James |
LONG BEACH, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN) ("BeautyHealth" or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the third quarter ended September 30, 2025 ("Q3 2025"). "Our third-quarter results reflect disciplined execution and the continued strengthening of BeautyHealth's foundation," said BeautyHealth President and CEO, Pedro Malha. "Revenue of $70.7 million and Adjusted EBITDA of $8.9 million exceeded the top end of our guidance range, supported by ongoing operational efficiency. While device sales remained under pressure, the recurring consumables business continued to demonstrate resilience an
LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced the appointment of global aesthetics leader, Philippe Schaison, PharmaD, to its Board of Directors, effective as of October 30, 2025. Dr. Schaison has spent over 20 years leading organizations across the global aesthetics, biotech, and consumer health industries. He currently serves as Chief Executive Officer and a director of Soltégo, Inc., a bio-cosmetic company. Previously, Dr. Schaison was Chief Executive Officer NA of Syneron Candela, President of Allergan Aesthetics, and held senior leadership roles at Clarins, Johnson & Johnson, and L'Oré
LONG BEACH, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report third quarter 2025 financial results after market close on Thursday, November 6, 2025. The Company will host an investor conference call at 4:30 p.m. Eastern Time, following a press release detailing the results. A live webcast of the call can be accessed on the Company's investor relations website at https://investors.beautyhealth.com, along with supporting materials. A recording of the call will become available on the site approximately three hours after its conclusion. Disclosure InformationThe Beauty Health Company announc
10-Q - Beauty Health Co (0001818093) (Filer)
8-K - Beauty Health Co (0001818093) (Filer)
8-K - Beauty Health Co (0001818093) (Filer)
4 - Beauty Health Co (0001818093) (Issuer)
4 - Beauty Health Co (0001818093) (Issuer)
3 - Beauty Health Co (0001818093) (Issuer)
Roth Capital initiated coverage of The Beauty Health Company with a rating of Buy and set a new price target of $3.50
Jefferies downgraded The Beauty Health Company from Buy to Hold and set a new price target of $1.50 from $11.00 previously
Canaccord Genuity downgraded The Beauty Health Company from Buy to Hold and set a new price target of $2.50 from $10.00 previously
4 - Beauty Health Co (0001818093) (Issuer)
LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced the appointment of global aesthetics leader, Philippe Schaison, PharmaD, to its Board of Directors, effective as of October 30, 2025. Dr. Schaison has spent over 20 years leading organizations across the global aesthetics, biotech, and consumer health industries. He currently serves as Chief Executive Officer and a director of Soltégo, Inc., a bio-cosmetic company. Previously, Dr. Schaison was Chief Executive Officer NA of Syneron Candela, President of Allergan Aesthetics, and held senior leadership roles at Clarins, Johnson & Johnson, and L'Oré
Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth LONG BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced the appointment of Pedro Malha as President and Chief Executive Officer, effective October 1, 2025. He succeeds Marla Beck, who is stepping down as President and CEO effective September 30, 2025, and will remain in an advisory role. Brent Saunders, Chairman of the Board, stated, "Pedro is an accomplished leader with broad industry experience at lea
The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced the appointment of two accomplished industry executives to its commercial leadership team. Ron Menezes will join Beauty Health as Chief Revenue Officer and Carrie Caulkins will join the Company as Chief Marketing Officer, effective October 15, 2024, with both reporting to the Company's Chief Executive Officer, Marla Beck. Mr. Menezes assumes his new role from Dan ("Doc") Watson, who is leaving Beauty Health and will assist with the transition through year-end. Ms. Caulkins fills an open position. Marla Beck commented on the appointments, "We are thrilled to welcome Ron and Carrie to the executive t
SC 13G/A - Beauty Health Co (0001818093) (Subject)
SC 13G/A - Beauty Health Co (0001818093) (Subject)
SC 13G/A - Beauty Health Co (0001818093) (Subject)
LONG BEACH, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN) ("BeautyHealth" or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the third quarter ended September 30, 2025 ("Q3 2025"). "Our third-quarter results reflect disciplined execution and the continued strengthening of BeautyHealth's foundation," said BeautyHealth President and CEO, Pedro Malha. "Revenue of $70.7 million and Adjusted EBITDA of $8.9 million exceeded the top end of our guidance range, supported by ongoing operational efficiency. While device sales remained under pressure, the recurring consumables business continued to demonstrate resilience an
LONG BEACH, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report third quarter 2025 financial results after market close on Thursday, November 6, 2025. The Company will host an investor conference call at 4:30 p.m. Eastern Time, following a press release detailing the results. A live webcast of the call can be accessed on the Company's investor relations website at https://investors.beautyhealth.com, along with supporting materials. A recording of the call will become available on the site approximately three hours after its conclusion. Disclosure InformationThe Beauty Health Company announc
Raises guidance on strong execution and disciplined cost management Advances science-backed innovation with successful launch of the HydraFillic with Pep9™ Booster LONG BEACH, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN) ("BeautyHealth" or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the second quarter ended June 30, 2025 ("Q2 2025"). "Momentum continued to build in the second quarter, as BeautyHealth delivered another strong performance aligned with our strategic transformation goals," said BeautyHealth CEO Marla Beck. "We exceeded revenue and Adjusted EBITDA expectations and raised the full year ou